Phase 2 Trial to Evaluate Safety and Efficacy of CYTO-205 in Mild COVID-19 (Study)

The LDN 2021 Conference Recordings Now Available with up to 29 CME Credits [More Details]

Medical Professionals Become an LDN Specialist [More Details]

Submitted by baileylynn_100964 on Thu, 03/25/2021 - 04:12

Phase 2 Trial to Evaluate Safety and Efficacy of CYTO-205 in Mild COVID-19

ClinicalTrials.gov
13 January 2021
https://www.clinicaltrials.gov/ct2/show/NCT04708327?term=Cytocom&draw=2&rank=1

The aim of the study is to assess the safety and clinical efficacy of low-dose naltrexone (CYTO-205; Cytocom, Inc) in reducing the proportion of higher risk patients who progress from mild COVID-19 to a more severe disease category.
 

Type of Video